Telitacicept

Drug identity checked against registry records

Also recorded as RC18; RC18-L

A drug appearing in a clinical trial does not mean it is FDA-approved. Check the original regulatory source for any approval claim.

Included trials

TrialSponsorPhaseStatusPrimary completion
A Study of Telitacicept for the Treatment of Moderately to Severely Active Systemic Lupus Erythematosus (REMESLE-1)NCT05306574Vor BiopharmaPhase 3Terminated2025-01-06Actual
Chinese Adults With Kidney DiseaseNCT07522099ADRXPhase 2Recruiting2028-07-10Estimated
Phase 3 Study of Telitacicept in Active Primary Sjögren's DiseaseNCT07404865Vor BiopharmaPhase 3Recruiting2028-12Estimated
A Study of Telitacicept for the Treatment of Generalized Myasthenia Gravis (UPSTREAM MG)NCT06456580Vor BiopharmaPhase 3Active not recruiting2027-03Estimated

Regulatory dates and decisions

No regulatory events match this view.This does not mean no FDA events have occurred.